Ignite Creation Date:
2024-05-06 @ 3:36 AM
Last Modification Date:
2024-10-26 @ 11:36 AM
Study NCT ID:
NCT02332512
Status:
UNKNOWN
Last Update Posted:
2017-02-24
First Post:
2015-01-04
Brief Title:
Study of Apatinib as 3rd4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor EGFR
Sponsor:
Jiangsu HengRui Medicine Co Ltd
Organization:
Jiangsu HengRui Medicine Co Ltd
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Phase III Trial of Apatinib as 3rd4th Line Treatment in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor EGFR
Status:
UNKNOWN
Status Verified Date:
2017-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ANSWER
Brief Summary:
Apatinib is a new kind of selective Vascular Endothelial Growth Factor Receptor 2VEGFR-2 tyrosine kinase inhibitor TKI The investigators have finished the preclinicalphase I and phase II clinical studies and found its promising anti-tumor activity and tolerable toxicities A disease-control rate of 611 and a mPFS of 47 months were showed in apatinib phase II study in patients with NSCLC
The study aims to compare the efficacy and safety of apatinib to placebo in advanced non-squamous non-small cell lung cancer patients
The study aims to compare the efficacy and safety of apatinib to placebo in advanced non-squamous non-small cell lung cancer patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None